Rehydragel HPA |
|
Vaxjo ID |
60 |
|
Vaccine Adjuvant Name |
Rehydragel HPA |
|
Adjuvant VO ID |
VO_0001311
|
|
Description |
Primary adjuvant in parenteral vaccine formulations. Does not generally induce cell mediated immunity(Vogel and Powell, 1995). |
|
Stage of Development |
Licensed |
|
Components |
Crystalline aluminum oxyhydroxide AlOOH, known minerologically as boehmite. the structure consists of corrugated sheets of aluminum octahedra. (Vogel and Powell, 1995). |
|
Preparation |
Synthetic oxyhydroxide of aluminum (aluminum hydroxide) prepared by acid-base precipitation(Vogel and Powell, 1995). |
|
Function |
Protein binding capacity: 2.5 mg BSA/mg Al2O3 minimum. The surface area, surface charge, and morphology of the aluminum hydroxide are major factors in its adjuvant characteristics. The use of aluminum adjuvants are accompanied by stimulation of IL-4 and stimulation of the T-helper-2 subsets in mice, with enhanced IgG1 and IgE production. (Vogel and Powell, 1995). |
|
Safety |
Can induce granulomas at the inoculation site (Vogel and Powell, 1995). |
| Related Vaccine(s) |
|
| References |
Vogel and Powell, 1995: Vogel FR, Powell MF. A compendium of vaccine adjuvants and excipients. Pharmaceutical biotechnology. 1995; 6; 141-228. [PubMed: 7551218].
|
